PEMAZA
MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse
| Studienleiter | Prof. Dr. med. Platzbecker |
|---|---|
| EudraCT-Nr. | 2017-004110-25 |
| Studientyp | Phase II |
| Indikation | AML |
| ClinicalTrial | NCT03769532 |